Most Common Side Effects of Tesamorelin
The most common side effects of tesamorelin are injection-site reactions (including erythema), arthralgia (joint pain), myalgia (muscle pain), paresthesia (tingling sensations), peripheral edema, and headache 1, 2, 3, 4.
Primary Side Effects Profile
Based on pooled analysis of phase 3 trials involving over 800 HIV patients, tesamorelin demonstrates a consistent adverse event pattern:
Injection-Site Reactions
- Most frequently reported adverse effect
- Manifests as erythema (redness), pain, irritation, or pruritus at injection sites
- Generally mild and do not lead to treatment discontinuation 2, 3, 4
Musculoskeletal Effects
- Arthralgia (joint pain) - common growth hormone-related effect
- Myalgia (muscle pain) - occurs in a substantial proportion of patients
- These symptoms are characteristic of growth hormone therapy and typically manageable 3, 4
Neurological Symptoms
- Paresthesia (tingling, numbness) - frequently reported
- Headache - common but usually mild
- These effects are dose-related and associated with growth hormone activity 1, 3
Other Common Effects
- Peripheral edema - fluid retention related to growth hormone effects
- Generally mild and transient 3, 4
Safety Profile Context
Treatment-emergent serious adverse events occurred in less than 4% of patients during 26 weeks of therapy 3. The medication was generally well tolerated across multiple trials, with most adverse events being mild to moderate in severity.
Important Metabolic Considerations
While not classified as "common side effects," clinicians should monitor:
- No clinically meaningful changes in glucose parameters were observed at 26 and 52 weeks in pooled analyses 2
- Tesamorelin showed no exacerbation of glycemic control even in patients on integrase inhibitors (associated with weight gain) 5
- IGF-1 levels increase significantly (expected pharmacologic effect, not an adverse event) 2
Recent Meta-Analysis Findings
A 2026 meta-analysis confirmed the established safety profile, noting that arthralgia, myalgia, paresthesia, and injection-site reactions like erythema remain the predominant adverse events, with no serious safety signals identified 1.
Clinical Pitfalls to Avoid
- Do not confuse expected pharmacologic effects (IGF-1 elevation) with adverse events - the increase in IGF-1 is the mechanism of action
- Injection-site reactions diminish with continued use - counsel patients that these typically improve over time rather than discontinuing prematurely
- Musculoskeletal symptoms are growth hormone-related - they reflect therapeutic activity rather than toxicity in most cases
- Monitor but don't overreact to glucose concerns - despite theoretical concerns with growth hormone therapy, clinical trials showed no clinically meaningful glucose changes 2, 5
The side effect profile is predictable, generally mild, and consistent with growth hormone-releasing hormone analogue activity, making tesamorelin well-tolerated for long-term use in appropriate patients.